While some past studies have compared the most effective first-line treatments for advanced NSCLC cases with these two types of EGFR driver mutations [66, 67], the emergence of more recent data from several major RCTs has largely rendered these earlier findings obsolete. Here, EGFR is linked to non-small cell lung carcinoma.